Compare Ginkgo Bioworks Holdings Inc (DNA) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Ryanair Holdings plc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Ryanair Holdings plc trades at $65.03 (market cap $31.19B). The key difference: Ryanair Holdings plc is far larger — about 52.8× Ginkgo Bioworks Holdings Inc's market cap, and Ryanair Holdings plc pays a 1.54% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | RYAAY | |
|---|---|---|
Market Cap | $590.53M | $31.19B |
Sector | Health | Industrials |
52-Week High | $16.14 | $73.82 |
52-Week Low | $5.48 | $53.24 |
Enterprise Value | $627.78M | $28.85B |
Dividend Yield | — | 1.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
RYAAY trades at $63.91, down 1.14% today, with a bullish technical signal from moving averages and neutral oscillators. The company shows strong profitability with a 13.98% net income margin and 25.37% ROE, supported by consistent earnings beats in recent quarters. Recent news includes a window incident investigation and CEO contract extension, while passenger traffic grew 7% year-over-year in June 2026 (Zacks Investment Research, 2026-07-02).
The outlook remains positive with analyst consensus at 62.5% buy ratings, though risks include rising fuel costs and regulatory scrutiny. Valuation appears reasonable with a P/E of 13.74 and EV/EBITDA of 6.57, suggesting potential upside if travel demand sustains. Near-term focus is on Q2 2026 earnings against expectations of $1.37 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
